Neste generasjons målrettet radiokonjugatbehandling for hematologiske kreft

Offentlig prosjektsammendrag

NucliThera aims to develop novel CD37-targeting vectors for use in targeted radionuclide therapy (TRT) for haematological malignancies. Existing therapies are limited by long circulation times, immunogenicity, and single-dose profiles. This project addresses the technical uncertainty of whether alternative vector formats can improve pharmacokinetics and enable repeat dosing. Through systematic R&D, the project will design, produce, conjugate, and radiolabel candidate vectors, followed by in vitro and pilot in vivo evaluation. The goal is to identify 5–10 promising candidates and reach a go/no-go decision for further development. The project will generate new knowledge on vector design and biological performance, laying the foundation for future therapeutic innovation.